SCHEMBL8142012

SCHEMBL8142012

COCC(=O)Nc1ccccc1N1CCNCC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
NPSR1 Q6W5P4 5/20 0.55
TSHR P16473 5/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
LMNA P02545 2/20 0.55
MAPK1 P28482 3/20 0.54
POLB P06746 2/20 0.54
MAPT P10636 2/20 0.54
ATM Q13315 2/20 0.54
USP2 O75604 1/20 0.54
ALOX15 P16050 1/20 0.54
GAA P10253 4/20 0.53
ALDH1A1 P00352 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
GFER P55789 1/20 0.52
KCNQ2 O43526 1/20 0.52
MCOLN3 Q8TDD5 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27402105 0.84 TSHR (0.75) MEN1KMT2ANPSR1TSHRL3MBTL1
SCHEMBL14356046 0.82 GAA (0.78) MEN1KMT2ANPSR1TSHRL3MBTL1
SCHEMBL7537046 0.80 CHEK1 (0.54) NPSR1L3MBTL1MAPT
SCHEMBL8133454 0.79 NPSR1 (0.54) MEN1KMT2ANPSR1TSHRL3MBTL1
SCHEMBL1646808 0.79 CHEK1 (0.55)
SCHEMBL8403429 0.77 NPSR1 (0.55) MEN1KMT2ANPSR1TSHRL3MBTL1
SCHEMBL6991512 0.77 CHEK1 (0.49) MEN1KMT2ANPSR1L3MBTL1MAPK1
SCHEMBL5558994 0.77 POLB (0.66) MEN1KMT2ANPSR1TSHRL3MBTL1
SCHEMBL14356002 0.77 CHEK1 (0.54) NPSR1L3MBTL1POLBMAPTGAA
Hydrochloric Acid SCHEMBL9489588 0.76 KMT2A (0.55) KMT2ANPSR1TSHRL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884107-B2 Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents MERCK (US) 2011-02-08 US disclosed
US-7884107-B2 Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents MERCK (US) 2011-02-08 US disclosed
WO-2008005268-A1 SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF SCHERING CORPORATION (US) 2008-01-10 WO disclosed
US-20080004287-A1 Substituted Piperidines that Increase P53 Activity and the Uses Thereof SCHERING CORPORATION 2008-01-03 US disclosed
US-20080004287-A1 Substituted Piperidines that Increase P53 Activity and the Uses Thereof SCHERING CORPORATION 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004287-A1 Substituted Piperidines that Increase P53 Activity and the Uses Thereof TP53, MDM2, TP53BP1 MEN1 3505/4885KMT2A 1308/4885NPSR1 3937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.